Mallika Singh

Mallika Singh is a seasoned professional in the biopharmaceutical industry with over 8 years of experience. She is currently pursuing a Doctor of Public Health (DrPH) degree at New York Medical College (NYMC). Mallika's research focuses on identifying systemic barriers to diverse representation in clinical trials and advocating for inclusive policies in recruitment and retention efforts.

Throughout her career, Mallika has held key roles in global biopharmaceutical companies such as Regeneron, Biogen, and Amgen, gaining experience in Clinical Operations, Pharmacovigilance (Drug Safety), and Pharmacokinetics and Drug Metabolism (PKDM). Her leadership role at Regeneron, where she spearheaded the implementation of a safety system and ensured regulatory adherence, has been instrumental in driving operational

excellence and enhancing patient safety across global clinical trials by automating the distribution of critical patient safety information. This reflects her dedication to patient-centricity and regulatory compliance. As a Senior Research Associate within the PKDM department at Amgen, her efforts were integral in measuring the half-life of the target protein KRAS, guiding dose projections, and advancing the development and approval of LUMAKRAS, a fast-tracked cancer therapy targeting non-small cell lung cancer (NSCLC).

Mallika's dedication to increasing diversity in clinical trials extends beyond her academic pursuits. She actively engages with advocacy groups, community organizations, and industry stakeholders to raise awareness about the importance of diverse representation in research studies. Through her research, advocacy, and leadership, she aspires to create a more inclusive and equitable healthcare system where all individuals have equal opportunities to participate in

and benefit from clinical research.